Walleye Trading
CMPX icon

Walleye Trading’s Compass Therapeutics CMPX Stock Holding History

Walleye Trading’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$132K Hold
25,000
– – ﹤0.01% 3329
2025
Q4 		$134K Hold
25,000
– – ﹤0.01% 3598
2025
Q3 		$87.5K Hold
25,000
– – ﹤0.01% 3772
2025
Q2 		$65K Hold
25,000
– – ﹤0.01% 3753
2025
Q1 		$47.5K Buy
+25,000
New +$66.5K ﹤0.01% 3620

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Walleye Trading's CMPX Position: Q1 2026 in Review

Walleye Trading held its Compass Therapeutics (CMPX) position steady in Q1 2026 at 25,000 shares worth $132K. The position accounts for ﹤0.01% of the portfolio, ranked #3329.

Walleye Trading first reported a position in CMPX in Q1 2025 and has held it in 5 quarters since. The position peaked at $134K in Q4 2025. 201 funds tracked by Wall St. Rank hold CMPX as of Q1 2026.

  • Walleye Trading held 25,000 shares of Compass Therapeutics worth $132K as of Q1 2026.
  • Walleye Trading left its Compass Therapeutics share count unchanged in Q1 2026.
  • Compass Therapeutics made up ﹤0.01% of Walleye Trading's portfolio in Q1 2026, its #3329 holding.
  • Walleye Trading first reported a position in Compass Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Walleye Trading's Compass Therapeutics position peaked at $134K in Q4 2025.
  • 201 funds tracked by Wall St. Rank held Compass Therapeutics as of Q1 2026.

Based on Walleye Trading's 13F filing for Q1 2026, filed 11 May 2026.